Evaluate Efficacy and Safety of IBI308 and Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma

Condition:   Efficacy and Safety
Interventions:   Biological: IBI308;   Biological: paclitaxel/ irinotecan
Sponsor:   Innovent Biologics (Suzhou) Co. Ltd.
Not yet recruiting - verified April 2017

http://ift.tt/2ou7LA6